Over 160 CEOs Sign MassBio’s Pledge to Create a More Equitable and Inclusive Life Sciences Industry

Sep 10, 2020

Leaders from across the industry commit to addressing racial inequality within their organizations through executive culture and other key areas

September 10, 2020 (CAMBRIDGE, MA) –  The Massachusetts Biotechnology Council (MassBio®) today announced that 164 CEOs representing the breadth of the life sciences have signed its Open Letter 2.0 – The CEO Pledge for a More Equitable and Inclusive Life Sciences Industry. This pledge serves as a call to action for CEOs across the life sciences to create change within their respective organizations and is a critical component of MassBio’s expanded equity, diversity, and inclusion (ED&I) initiative rolled out earlier this year.

By signing this letter, a CEO recognizes that racial inequity exists in the life sciences industry and in his/her company and is taking responsibility to fix that injustice through comprehensive ED&I initiatives that are broad in scope, specific in action, and measurable in results. The pledge is a long-term commitment dedicated to moving the industry forward over the next several years. The CEOs that signed the letter represent small and emerging biotechs, midsized companies, and large biopharmaceutical companies.

“Decades-long systematic racism and healthcare inequities plague our nation, and we must eradicate that from our industry whose mission is to treat, cure, and heal. That is the impetus behind MassBio’s Open Letter 2.0 – to ensure companies from across the life sciences are taking measurable steps to address these issues,” said Edie Stringfellow, Director of Diversity and Inclusion, MassBio. “MassBio is heartened by the response to the pledge and applaud the unwavering commitment of these CEO signers to address equity, diversity, and inclusion. I look forward to working with each CEO to implement broad, lasting change in the life sciences in the coming years.”

The pledge outlines six areas that must be addressed. These include: leadership and executive culture, inclusive company culture, recruitment, retention and development, accountability and sustainability, and supplier diversity. Each pillar outlines several opportunities for a company to improve in that specific area and a CEO must commit him or herself to at least one of the actions.

“There is still so much to be done to promote racial equity in our society, and we as leaders in the life sciences have a responsibility and a tremendous opportunity to drive change within our own companies and lift up our community more broadly,” said Cindy Perettie, CEO, Foundation Medicine. “Our goal in supporting this critical initiative is not only to move our own industry forward, but to inspire and push others as well.”

“We’re living through an unprecedented time, and one where our industry is viewed as offering critical solutions to the COVID-19 pandemic,” said Chip Clark, President and CEO, Genocea Biosciences, Inc. “The life sciences must capitalize on this opportunity not only to help heal the world, but also to demonstrate leadership through immediate and sustained actions addressing racial and social injustices that have long suppressed minority populations. I’m proud to sign the Pledge and commit myself and my company to such necessary actions.”

In developing this letter, MassBio also acknowledges its role as a leader in the industry and pledges itself to assist the cohort of CEO signers as needed through one-on-one meetings, forums, and shared resources.

You can read the full letter and view the CEOs who have pledged their name here. To learn more about MassBio’s ongoing work to improve equity, diversity, and inclusion in the life sciences, please visit: https://www.massbio.org/initiatives/equity-diversity-and-inclusion/.

Open Letter 2.0 Signers

Acceleron PharmaHabibDableCEO
Accent TherapeuticsShaktiNarayanCEO
AddgeneJoanneKamensExecutive Director
Agios PharmaceuticalsJackieFouseCEO
AkiliEddieMartucciPresident & CEO
Aldeyra TherapeuticsToddBradyPresident & CEO
Aleta BiotherapeuticsMarkLeuchtenbergerExecutive Chairman
AlkermesRichardPopsChairman & CEO
Ally TherapeuticsTinaLiuCEO
Alnylam Pharmaceuticals, Inc.JohnMaraganoreCEO
ALS Therapy Development InstituteStevenPerrinCEO
Anelixis TherapeuticsStevenPerrinCEO
Anika TherapeuticsCherylBlanchardPresident & CEO
AnokionJohnHohnekerPresident & CEO
Apellis PharmaceuticalsCedricFrancoisCEO
Aphios CorporationTrevorCastorCEO
Arranta BioMarkBamforthPresident & CEO
Atalanta TherapeuticsAliciaSecorPresident & CEO
Aviceda TherapeuticsMohamedGenead, MDCEO & Co-Founder
Bayer U.S. LLCPhilipBlakePresident
BigBio CommunicationsTiltonLittleCEO
Biotech Vendor Services, Inc.PamelaGardnerPresident & CEO
bluebird bioNickLeschlyCEO
Blueprint MedicinesJeffAlbersCEO
Boston PharmaceuticalsRobArmstrongCEO
CairnSurgical, Inc.DavidDanielsenCEO
Captivate BioTanyaPotcovaFounder & CEO
Cedilla TherapeuticsAlexandraGlucksmannPresident & CEO
Celdara Medical, LLCJakeRederPresident & CEO
CellinoNabihaSaklayenCEO & Co-Founder
Cend Therapeutics, Inc.DavidSlackPresident & CEO
Cerevel TherapeuticsTonyColesChairman & CEO
Checkmate PharmaceuticalsBarryLabingerPresident & CEO
Codiak BioSciencesDouglasWilliamsPresident & CEO
Cohere Business StrategiesJeffreyKiplingerOwner & Principal
Constellation PharmaceuticalsJigarRaythathaCEO
Danforth AdvisorsChrisConnorsPresident
Decibel TherapeuticsLaurenceReidCEO
Deciphera PharmaceuticalsSteveHoerterCEO
Disc Medicine, Inc.JohnQuiselPresident & CEO
eClinical Solutions LLCRajIndupuriCEO
EMD SeronoRehanVerjeePresident – EMD Serono
Entasis TherapeuticsManosPerrosPresident & CEO
Entera BioAdamGridleyCEO
Epizyme, IncRobertBazemorePresident & CEO
EQRx, Inc.AlexisBorisyFounder, Chairman & CEO
Evelo BiosciencesSimbaGillCEO
Finch TherapeuticsMarkSmithCEO
Flexion TherapeuticsMichaelClaymanCEO
FOG Pharmaceuticals, Inc.GregVerdineChairman & CEO
Forma TherapeuticsFrankLeeCEO
Foundation MedicineCindyPerettieCEO
Frequency TherapeuticsDavidLucchinoPresident & CEO
g.Root Biomedical Services, Inc.ChesleyChenCEO
Gamida Cell TherapiesJulianAdamsCEO
Genuity ScienceRobBraininCEO
German Accelerator Life SciencesMarcFilermanCEO
Goldfinch BioAnthonyJohnsonPresident & CEO
GreenLight BiosciencesAndreyZarurCEO
Gritstone OncologyAndrewAllenCEO
Halloran Consulting GroupLaurieHalloranPresident & CEO
HealthScape LifeSciences  LLCHeleneClayton-JeterFounder & CEO
Hiller Life Sciences Strategies, LLCArthurHillerOwner and Principal
Ikena OncologyMarkManfrediCEO
InnoGenomics Technologies, LLCSudhirSinhaCEO
IpsenRichardPaulsonCEO, Ipsen North America
Jnana TherapeuticsJoanneKotzCEO
Jounce TherapetuicsRichardMurrayCEO
Karuna TherapeuticsStevePaulChairman, President & CEO
Kymera TherapeuticsNelloMainolfiFounder, President & CEO
Life Biosciences Inc.MehmoodKhanCEO
Life Science CaresSarahMacDonaldExecutive Director
LifeMine TherapeuticsGregVerdinePresident & CEO
MacDougall AdvisorsKariWatsonCo-Founder & Managing Partner
Magenta TherapeuticsJasonGardnerPresident & CEO
Massachusetts Life Sciences CenterDamonCoxInterim President & CEO
MassBioRobertCoughlinPresident & CEO
Medley GenomicsPatriceMilosCo-Founder & CEO
Mersana TherapeuticsAnnaProtopapasPresident & CEO
MilliporeSigmaChrisRossSector Head
Morphic TherapeuticPraveenTipirneniPresident & CEO
Navitor PharmaceuticalsTomHughesCEO
Nimbus TherapeuticsJebKeiperCEO
North Shore InnoVenturesChristopherIlsleyCEO & President
Novartis Institutes for BioMedical ResearchJayBradnerPresident
NuritasNoraKhaldiFounder & CEO
Obatala Sciences, IncTriviaFrazierPresident & CEO
Ohana BiosciencesAmberSalzmanCEO
Ophthalmic Therapeutic InnovationTina GuantingQiuPrincipal/Chief Strategic Innovation
Ora, Inc.JeanneHechtCEO
Orchard TherapeuticsBobbyGasparCo-Founder & CEO
PfizerAlbertBourlaChairman & CEO
PHASTARKevinKaneCEO & Founder
Pieris PharmaceuticalsStephenYoderPresident & CEO
QuanterixKevinHrusovskyChairman and CEO
Quench Bio, Inc.SamanthaTruexCEO
Relay TherapeuticsSanjivPatelCEO
ReNetX BioErikaSmithCEO
Rheos MedicinesBarbaraFoxCEO
ROME TherapeuticsRosanaKapellerPresident & CEO
Rubius TherapeuticsPabloCagnoniPresident & CEO
Rubix LSReginaldSwiftFounder & CEO
SanionaRamiLevinPresident & CEO
SanofiBillSiboldPresident, Sanofi, North America
Sarepta TherapeuticsDouglasIngramPresident & CEO
Seeding LabsMelissaWuCEO
Servier Pharmaceuticals LLCDavidLeeCEO
SmartPharm TherapeuticsJoséTrevejoCEO & Co-Founder
Society for Participatory MedicineDanielSandsCo-Chair & Co-Founder
Solid BiosciencesIlanGanotCEO
Spero TherapeuticsAnkitMahadeviaCEO
STEIN+PARTNERSAliceSteinPresident & Founder
Stoke TherapeuticsEdwardKayeCEO & Director
Surface OncologyJeffGoaterPresident & CEO
Synlogic TherapeuticsAoifeBrennanPresident & CEO
SyrosNancySimonianPresident & CEO
Takeda Pharmaceuticals CompanyRamonaSequeiraPresident, US Business Unit and Global Portfolio Commercialization
Talaria Antibodies IncShawnaWicksCEO
Talaris TherapeuticsScottRequadtCEO
Tango TherapeuticsBarbaraWeberPresident & CEO
Ten Bridge CommunicationsDanQuinnCEO
The BioPharma HubSteveWoitExecutive Director
The M1 Project,  llcJimMurphyPresident
The NemetzGroup LLCSusanNemetzCEO & Founder
Thermo Fisher Scientific Inc.MarcCasperChairman, President & CEO
Third Rock VenturesAbbieCelnikerPartner
Tiburio TherapeuticsAbrahamCeesayCEO
TMS BioScience LabsPleasantHooperPresident
Translate BioRonRenaudCEO
Triplet TherapeuticsNessanBerminghamCEO
Tunnell ConsultingMaryannGallivanPresident & CEO
UCBDuaneBarnesPresident and Head, U.S. Operations
Unum Therapeutics Inc.ChuckWilsonPresident & CEO
Upshift InnovationTravisMcCreadyFounder & Principal
USH Consulting LLCSimoneAzevedoCEO/Founder
Vedanta BiosciencesBernat OlleCEO
Verve TherapeuticsSekarKathiresanCEO
Vir BiotechnologyGeorgeScangosCEO
Women in the Enterprise of Science and Technology (WEST)MeenaSubramanyamPresident
X4 PharmaceuticalsPaulaRaganCEO
X-Biotix Therapeutics, Inc.RamaniVaranasiPresident & CEO
Xilio TherapeuticsReneRussoCEO
Yumanity TherapeuticsRichardPetersCEO
Zealand PharmaEmmanuelDulacPresident & CEO

See all MassBio News